Prostatype Genomics AB Working Capital to Net Assets Ratio
Prostatype Genomics AB working capital to net assets ratio. Prostatype Genomics AB (PROGEN) has a Working Capital to Net Assets ratio of 19.2% as of June 2025. Working capital of Skr7.01 Million (current assets of Skr14.37 Million minus current liabilities of Skr7.36 Million) is measured against net assets of Skr36.48 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check Prostatype Genomics AB tangible equity quality to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Prostatype Genomics AB (2015–2024)
Working capital to net assets ratio of Prostatype Genomics AB from 2015 to 2024. This chart shows how Prostatype Genomics AB's Working Capital to Net Assets ratio has evolved across 9 annual periods from 2015 to 2024. As of June 2025, the ratio stands at 19.2%, reflecting working capital of Skr7.01 Million against net assets of Skr36.48 Million SEK. See Prostatype Genomics AB defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Prostatype Genomics AB Working Capital to Net Assets Ratio by Year (2015–2024)
Prostatype Genomics AB working capital to net assets ratio by year from 2015 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Prostatype Genomics AB from 2015 to 2024, covering 9 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see PROGEN total asset value.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 9.9% | Skr3.32 Million | Skr33.47 Million | Skr11.82 Million | Skr8.50 Million | ▲ +4.1 pp |
| 2023 | 5.8% | Skr1.43 Million | Skr24.67 Million | Skr25.91 Million | Skr24.48 Million | ▼ -31.8 pp |
| 2022 | 37.6% | Skr9.84 Million | Skr26.15 Million | Skr14.17 Million | Skr4.33 Million | ▼ -13.0 pp |
| 2021 | 50.6% | Skr18.15 Million | Skr35.91 Million | Skr21.59 Million | Skr3.43 Million | ▲ +4.1 pp |
| 2020 | 46.5% | Skr13.15 Million | Skr28.29 Million | Skr17.46 Million | Skr4.31 Million | ▲ +24.2 pp |
| 2018 | 22.2% | Skr1.90 Million | Skr8.55 Million | Skr4.48 Million | Skr2.58 Million | ▼ -70.4 pp |
| 2017 | 92.6% | Skr5.76 Million | Skr6.22 Million | Skr9.70 Million | Skr3.94 Million | ▲ +36.3 pp |
| 2016 | 56.3% | Skr8.41 Million | Skr14.93 Million | Skr11.17 Million | Skr2.76 Million | ▲ +195.1 pp |
| 2015 | -138.7% | Skr1.83 Million | Skr-1.32 Million | Skr3.43 Million | Skr1.60 Million | — |